ACET
Adicet Bio Inc
Adicet Bio Inc
$ACET reports strong pipeline progress and financial results for Q4 2022
Adicet Bio has reported strong financial results for Q4 and the year ended December 31st, 2022. The clinical stage biotechnology company has made progress in advancing its gamma delta T cell therapy pipeline and clinical proof of concept. Adicet is enrolling patients for its ongoing trial for relapsed or refractory B-cell NHL and expects to submit an IND for ADI-925 in H2 2023. The company presented preclinical data for four new pipeline programs at SITC Annual Meeting last November, and its cash and cash equivalents securities are expected to be sufficient to fund its operating expenses into H1 2025.
14d ago
$ACET